Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mindset Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mindset Pharma's position in the market.
On August 26, 2021, Mindset Pharma (OTCQB: MSSTF) announced promising preclinical results for its Family 3 compounds, which are long-acting psilocybin analogs. These compounds demonstrated a significantly reduced effect size on the 5-HT2A receptor, suggesting enhanced safety and efficacy for microdosing therapies. The findings indicate potential for effective low-dose administration without the hallucinogenic effects typical of psilocybin. The company plans further testing in preclinical models to explore cognitive benefits.
Mindset Pharma Inc. (OTCQB: MSSTF) has filed a new provisional patent application with the USPTO for its Family 4 compounds, which are novel DMT/5-MeO-DMT analogs. This new application expands the range of drug candidates and their synthesis processes. CEO James Lanthier highlighted the pharmacological diversity of these compounds, which may provide more personalized therapies in clinical settings. The company is moving closer to human clinical trials after successful preliminary in-vitro and in-vivo tests.
Mindset Pharma Inc. (OTCQB: MSSTF) has announced the publication of three PCT patent applications covering novel compounds designed to enhance the therapeutic effects of psilocybin. These applications include a range of proprietary compounds with lower safety liabilities and improved efficacy. CEO James Lanthier emphasized the first-to-file advantage and ongoing testing to validate these compounds. The Family 1 compounds aim to improve pharmacokinetics, while Family 2 compounds are set for clinical trials. This development underscores Mindset's commitment to advancing psychedelic medicine.
Mindset Pharma Inc. (OTCQB: MSSTF) has reported promising results from its next-generation psychedelic compounds, which include psilocybin/psilocin and DMT/5-MeO-DMT analogs. These compounds displayed enhanced efficacy, safety, and shorter durations compared to traditional drugs in preclinical tests. Initial studies indicate that Family 2 compounds show up to 10 times the efficacy of psilocin, while Family 4 compounds exhibit diverse pharmacological effects. Mindset aims to optimize these compounds for clinical settings, progressing towards human trials.
Mindset Pharma (OTCQB:MSSTF) announced the filing of an international patent application for its innovative psilocybin synthesis method, claiming priority from a prior U.S. filing dated July 24, 2020. This synthesis process promises advantages including lower cost, milder reaction conditions, and suitability for large-scale manufacturing. The company is collaborating with a leading CDMO for optimization and plans to initiate pilot-scale synthesis by 2021's end. Mindset's CEO highlighted the potential for significant demand in cGMP psilocybin for ongoing trials, showcasing a strong revenue opportunity.
Mindset Pharma Inc. (OTCQB: MSSTF) has appointed Dr. Ishrat Husain to its Scientific Advisory Board to guide the development of regulatory pathways for its novel psychedelic therapies. Dr. Husain, an expert in mood disorders, is currently engaged in clinical trials and has published over 40 research papers. His extensive experience in clinical trials and psychiatry will aid Mindset as it progresses toward FDA approval, aiming to provide effective treatments for mental illness. This milestone reflects Mindset's commitment to advancing psychedelic-inspired therapeutic solutions.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its lead psychedelic drug candidate, MSP-1014, exhibits superior efficacy and safety in pre-clinical tests compared to psilocybin. Using the mouse head twitch response assay, MSP-1014 showed over double the response of psilocybin without reducing locomotor activity or causing temperature changes. CEO James Lanthier highlighted MSP-1014's potential as a safer, scalable treatment for neuropsychiatric disorders. The company continues to develop a diverse pipeline of next-generation psychedelic medicines.
Mindset Pharma (OTCQB: MSSTF) announced a partnership with InterVivo Solutions to launch the Cooperative Psychedelics Evaluation Platform (COPE). This program aims to establish preclinical data benchmarks for psychedelic drugs like psilocybin and LSD. Preliminary data indicates a strong correlation between human clinical exposure and animal model efficacy, potentially enhancing drug development processes. Mindset's CEO expressed optimism about the insights gained, which are intended to address unmet needs in mental health treatments.
Mindset Pharma Inc. (CSE: MSET, OTCQB: MSSTF) announced the selection of MSP-1014 as its lead clinical candidate, based on superior safety and efficacy compared to psilocybin in preclinical studies. The compound is set to move into cGMP manufacturing and IND-enabling studies, marking a key milestone for the company. MSP-1014 aims to treat various mood disorders with potentially reduced side effects and lower clinical doses. Mindset continues to innovate in developing next-generation psychedelic medicines for unmet medical needs.